What question did this study set out to answer?

The study aims to find the optimal timing for MRI evaluations after chemoradiotherapy treatment in squamous cell carcinoma of the anus.

February 26, 2026Open Access

Optimal time for MRI response evaluation in squamous cell carcinoma of the anus

Key Points

The study aims to find the optimal timing for MRI evaluations after chemoradiotherapy treatment in squamous cell carcinoma of the anus.
Retrospective mono-center study with consecutive patients treated between 2013-2017.
MRI evaluations conducted at 6, 12, and 24 weeks post-treatment to detect locoregional treatment failures.
Tumor regression assessed using a combined tumor regression grade (comrTRG) based on MRI reports.
Mixed-effects logistic regression analysis stratified by T/N stage and HPV status.
Out of 127 patients, 13 experienced locoregional treatment failures; the majority were high-risk.
The rates of radiologic complete response increased at each time point: 27% at 6 weeks, 66% at 12 weeks, and 75% at 24 weeks.
Positive predictive value (PPV) of MRI improved significantly over time: 33% at 6 weeks, 46% at 12 weeks, and 88% at 24 weeks.
Negative predictive value (NPV) remained consistently high, above 90%.

Abstract

Abstract Objectives To identify the optimal time for MRI response evaluation after chemoradiotherapy (CRT) in squamous cell carcinoma of the anus (SCCA) and to employ combined T2+diffusion-weighted MRI tumor regression grade (comrTRG). Methods We assessed the positive and negative predictive values (PPV, NPV) of post-treatment MRI in a retrospective mono-center diagnostic accuracy study that prospectively included consecutive patients treated between 2013-2017. Index tests were MRI at 6-, 12-, and 24-weeks post-treatment (6w, 12w, 24w) to detect locoregional treatment failures (LRTF). Clinical outcome served as reference standard. Tumor regression was assessed using comrTRG based on radiological reports. Mixed-effects logistic regression was used to compare the comrTRG score across time points. The analyses were stratified by patients` T/N stage and human papillomavirus (HPV) status. Results For 127 included patients (62 years ± 11 mean±SD; 92 women), 261 post-treatment MRI reports (6w: n = 45, 12w: n = 125, 24w: n = 91) were scored using comrTRG. LRTF occurred in 13 patients; 12/13 were high-risk patients (T3/T4, N+, or HPV-negative); 1/13 progressed early (24 weeks). The rate of radiologic complete response (comrTRG1) increased over time (6w: 27%, 12w: 66%, 24w: 75%), while the rate of indeterminate (comrTRG2) and minor definite tumor (comrTRG3) decreased. PPV of MRI increased over time: 6w: 33% (95%CI: 9.9-65.1%), 12w: 46% (16.7-76.6%), and 24w: 88% (47.3-99.7%). NPV was stable high 90%. Conclusion MRI performed more reliably after 24 weeks. Timely assessment may aid early LRTF detection. Tailoring follow-up with frequent MRI scans may be sufficient for high-risk patients. Combined mrTRG is practical for describing response in SCCA. Advances in knowledge Post-treatment MRI assessment at later time points is preferable in SCCA to avoid inconclusive imaging and unnecessary salvage surgery. The introduced comrTRG is a practical tool for response evaluation. Registration ClinicalTrials.gov: NCT01937780

Read Full Paperexternally

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper